2 results
Approved WMORecruiting
To compare the therapeutic benefit of maintenance pazopanib versus placebo after first line treatment of NSCLC.
Approved WMORecruiting
Primary objectiveTo demonstrate that talazoparib in combination with enzalutamide is superior to placebo in combination with enzalutamide in prolonging investigator--assessed Radiographic Progression-free Survival (rPFS), in participants with mCSPC…